Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Oxurion NV Business Update – Q3 2018

19 Oct 2018

 Shareholders’ Approval and Launch of Oxurion NV as new Company Name 
First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) 
First Patient enrolled in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) 
End Q3 2018 cash position €95.1 million 

 Highlights 

  • Following shareholders’ approval on September 3, ThromboGenics NV was rebranded Oxurion NV. 
    The new name Oxurion better reflects the Company’s ambition to deliver best in class therapies for back of the eye disorders. The decision to rebrand coincides with the company reaching important milestones with its innovative diabetic eye disease pipeline, and the start of additional clinical studies.
  • First patient enrolled in Phase 1 clinical study evaluating THR-687, a novel pan-RGD integrin antagonist, for the treatment of DME
  • First patient enrolled in Phase 2 clinical study evaluating THR-317 (anti-PlGF) for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) 
  • Oxurion NV presented further scientific findings at EURETINA supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease 
  • Cash and investments were €95.1 million as of the end of September 2018, compared with €101.4 million at the end of June 2018 

Leuven, Belgium, 19 October 2018 – Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, today issues a business update for the three-month period ending 30 September 2018. Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edema (DME).

 The Oxurion pipeline consists of products with different modes of action, and includes: 

THR-317 – a PIGF (human placental growth factor) neutralizing monoclonal antibody, is in a Phase 2 study evaluating the efficacy and safety of intravitreal THR-317 when administered in combination with ranibizumab (Lucentis®), for the treatment of DME.  

In addition, THR-317 is being evaluated in a Phase 2 study for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1). MacTel 1 is a rare disease that affects the macula and can lead to vision loss. 

THR-149 – a plasma kallikrein inhibitor being developed for the treatment of DME. THR-149 is in a Phase 1 open-label, multicenter, dose escalation study 

THR-687 – a small molecule integrin antagonist being developed to treat a broad range of patients with diabetic eye disease. THR-687 entered the clinic in September 2018. 

Patrik De Haes, MD, CEO of Oxurion nv, commented: “This past quarter will be marked by the introduction of our new company name as we continue to make excellent progress in advancing our novel drug candidates in the clinic to treat diabetic eye disease. We began the clinical development of THR-687 as planned, and we started a new Phase 2 study evaluating THR-317 for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1). Earlier in the year we already announced the start of a Phase 2 study of THR-317 in combination with ranibizumab (Lucentis®) and a Phase I study with THR-149, both which are being developed for the treatment of DME. We look forward to the continued clinical advancement of our industry leading pipeline and expect to present initial clinical data in the second half of 2019.” 

 

Press release attachment: 
Tags: 
Company
Investors